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The association of TAFI (Thrombin-activatable fibrinolysis
inhibitor) with insulin resistance and components of metabolic
syndrome in patients with metabolic syndrome
Alev KURAL1, Ahmet OMMA2, Hatice SEVAL1, Macit KOLDAŞ1, Namık YİĞİT2, Tülay OMMA2

Aim: To investigate the association of TAFI with components of metabolic syndrome and insulin resistance in patients
with metabolic syndrome.
Materials and methods: Patients between 20 and 70 years of age, who met at least 3 of the metabolic syndrome criteria,
and had no known coronary artery disease were included in the study. The control group consisted of 20 healthy subjects
with demographic characteristics similar to the patients. Fasting blood glucose, HbA1c, lipid profile, insulin,
microalbumin, and TAFI Ag levels were investigated in the patients and controls. Insulin resistance was calculated
according to the HOMA-IR [(fasting plasma insulin (μIU/ml) × fasting plasma glucose (mmol/L))/22.5] formula.
Results: There was a significant difference (P < 0.01) between patients with metabolic syndrome (MS) and healthy
individuals with respect to TAFI Ag levels. However, when patients with MS were divided into 2 groups according to
HOMA-IR values, an indicator of insulin resistance, no association was detected between the levels of HOMA-IR and
TAFI Ag. In metabolic syndrome group, there was a positive correlation only between the triglyceride and plasma TAFI
Ag levels (P < 0.05).
Conclusion: These findings suggest that increased TAFI levels in metabolic syndrome may contribute to prothrombotic
state and impaired fibrinolysis, and that hypertriglyceridemia may play part in this process.
Key words: Metabolic syndrome, TAFI, insulin resistance

Metabolik sendromlu hastalarda insulin direnci ve metabolik sendrom
komponentleriyle TAFI (Thrombin activatable fibrinolysis inhibitor)
arasındaki ilişki
Amaç: Metabolik sendromlu hastalarda metabolik sendrom komponentleriyle, insülin direnci ve fibrinolitik sistemin
önemli bir inhibitörü olan TAFİ arasındaki ilişkiyi araştırdık.
Yöntem ve gereç: Hastalar yaşları 20-70 arasında olan, metabolik sendrom kriterlerinden en az 3’ünü taşıyan, bilinen
koroner arter hastalığı olmayan kişiler arasından seçildi. Hasta grubuyla benzer demografik özellikleri taşıyan 20 sağlıklı
kontrol grubu oluşturuldu. Hasta ve kontrol grubuna AKŞ, HbA1c, lipid profili (kolesterol, trigliserid, HDL kolesterol,
LDL kolesterol), insülin, 24 saatlik idrarda mikroalbümin, ve TAFI Ag parametrelerine bakıldı. İnsülin ve plazma glukozu
göz önüne alınarak HOMA-IR (açlık plazma insulin (μIU/mL) × açlık plazma glukozu (mmol/L)]/22.5) formülüne göre
insülin direnci hesaplandı.
Bulgular: Metabolik sendromlu hastalarda, TAFI Ag düzeylerini sağlıklı grupla karşılaştırdığımızda ileri düzeyde anlamlı
fark vardı (P < 0,01). Ama insülin rezistansının bir göstergesi olan HOMA-IR değerlerine göre metabolik sendromlu
hastaları kendi içinde 2 gruba ayırdığımızda HOMA-IR düzeyi ile TAFI Ag arasında ilişki saptayamadık. Literatürden
farklı olarak metabolik sendrom grubunda total kolesterol, HDL-kolesterol, LDL-kolesterol, açlık kan şekeri, BMI, bel
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çevresi, mikroalbüminüri ile plazma TAFI Ag düzeyi arasında ilişki saptayamadık. Metabolik sendromda sadece
trigliserid düzeyi ile plazma TAFI Ag düzeyi arasında pozitif korelasyon saptadık (P < 0,05).
Sonuç: Bu bulgular bize metabolik sendromdaki artmış TAFI düzeylerinin protrombotik duruma ve bozulmuş
fibrinolizise bir katkı sağlayabileceğini ve bu katkıda hipertrigliserideminin de rolü olabileceğini düşündürmektedir
Anahtar sözcükler: Metabolik sendrom, TAFI, insülin direnci

Introduction
Metabolic syndrome (MS), also known as insulin
resistance syndrome, is defined by the clustering of
several cardiovascular risk factors in an individual
patient, including impaired glucose tolerance
(diabetes), hypertension, dyslipidemia, and visceral
obesity. Several studies have demonstrated that this
syndrome strongly predicts cardiovascular disease
(CVD), especially coronary heart disease,
independently of LDL-cholesterol levels (1). Since the
original description of metabolic syndrome in 1988,
criteria diagnosis develop constantly and a complete
consensus has yet to be reached on the most proper
definition. Criteria suggested for MS may partly vary
depending upon its pathogenesis. Insulin resistance is
the main cause of metabolic syndrome. According to
International Diabetes Foundation (IDF), central
obesity plays a key role in the pathogenesis of MS and
is the sine qua non diagnostic criterion (2). IDF
stressed the presence of ethnic differences in the
correlation between central obesity and other risk
factors. Therefore, the criteria of central obesity were
determined based on nation and ethnicity using the
best available population estimates. For the people of
European origin, IDF determined the threshold value
for abdominal obesity ≥94 cm waist circumference in
males and ≥80 cm in females. In Asian populations
other than Japanese, threshold values are ≥90 cm and
≥80 cm in males and females, respectively. Probably
one of the most commonly used criteria is those of
National Cholesterol Education Program–Adult
Treatment Panel III (NCEP ATP III). These criteria
were modified in 2005 and the cut off value of fasting
blood sugar was reduced from 110 mg/dL to 100
mg/dL (3). The criteria for metabolic syndrome are
listed as follows:
1) Updated NCEP ATP III, 2005
Three or more of the following 5 risk
abnormalities:
858

a) Waist circumference > 102 cm (men) or > 88
cm (women)
b) Triglycerides > 150 mg/dL
c) HDL-Cholesterol < 40 mg/dL (men) or < 50
mg/dL (women)
d) Blood pressure > 130/85 mm Hg
e) Fasting plasma glucose > 100 mg/dL
2) IDF Criteria, 2005
Increased waist circumference (with ethnicityspecific values for ethnic groups) plus at least 2 of the
following:
a) Triglycerides >150 mg/dL or treatment for this
abnormality
b) HDL-C < 40 mg/dL (men) or < 50 mg/dL
(women) or specific treatment
c) Blood pressure >130/85 mm Hg or specific
treatment
d) Fasting plasma glucose > 100 mg/dL or
previously diagnosed type 2 diabetes
In MS, hypercoagulability is the consequence of
the increase in coagulation factors, decrease in
fibrinolysis, hyperactivity and thrombocytes, and
endothelial dysfunction. Insulin resistance plays a
central role in pathogenesis. According to the formula
of homeostasis of minimal assessment of insulin
resistance (HOMA-IR), a value of >2.5 is defined as
insulin resistance (4). Thrombin activatable
fibrinolysis inhibitor (TAFI) provides an important
molecular link between the coagulation and
fibrinolytic systems (5). TAFI is a 58-kD glycoprotein
synthesized in the liver and can be activated by
thrombin, thrombin-thrombomodulin complex,
plasmin or trypsin-catalyzed proteolysis to
carboxypeptidase B –like enzymes that inhibit
fibrinolysis (6). It is well known that C-terminal
lysines on cell-surface proteins and partially degraded
fibrin enhance fibrinolysis by providing binding sites
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for plasminogen. Once bound, it adopts a more
activatable conformation. Activated TAFI inhibits
activation of plasminogen to plasmin by removing
these C-terminal lysine residues. In addition,
activated TAFI might also directly inactivate plasmin,
further impairing fibrinolysis (7). Since TAFI is
associated with coagulation/fibrinolysis and
inflammation, plasma TAFI may participate in
arterial thrombosis in CVD or in venous thrombosis
(8). In a previous study of patients with type 2 diabetes
(9), plasma TAFI was independently correlated with
components of the MS including visceral fat and the
glucose infusion rate, an index of insulin resistance.
However, Aubert et al. (10) suggested that plasma
TAFI shows only a weak, non-independent
correlation with insulin resistance. Thus, the identity
of main determinants of plasma TAFI concentrations
remains unclear.
Despite studies on the relationship of TAFI with
thromboembolic events and coronary artery disease
of various metabolic syndromes, studies on
association of TAFI and neoplastic disease are limited
(11-14).
Study design and methods
A total of 83 individuals including 63 patients from
Haseki Training and Research Hospital and 20 healthy
controls were included in the study. Patients with an
age range of 20-70 years were selected among
individuals without any known coronary artery
disease, who presented to the Internal Medicine
Outpatient Clinics and fulfilled at least 3 of the
metabolic syndrome criteria (Updated NCEP ATP III,
IDF). Presence of previous coronary cardiac disease,
chronic airway disease, and impaired hepatic
dysfunction, pregnancy, and presence of any acute
disease were determined as exclusion criteria.
Demographic characteristics of patient and control
groups were similar. The study protocol was approved
by the institutional ethics committee. All participants
gave informed consent before recruitment. Fasting
blood glucose (FBG), HbA1c, lipid profile (total
cholesterol, triglyceride, HDL-cholesterol, and LDLcholesterol), insulin, 24-h urinary microalbumin, and
TAFI Ag levels were investigated in the patient and
control groups. Glucose, cholesterol, triglyceride, and
HDL-cholesterol
were
measured
by
a
spectrophotometric method with an Olympus AU

2700 device using Olympus kits, and HbA1c was
measured by immuno-turbidimetric inhibition
method with the same device using the same kits.
Insulin was measured by chemiluminescence method
using an Immulite 2000 device. Insulin resistance was
calculated using insulin and plasma glucose,
according to homeostasis of minimal assessment of
insulin resistance (HOMA-IR) [(fasting plasma
insulin (μIU/mL) × fasting plasma glucose (mmol/L))
/ 22.5] formula. TAFI Ag was measured by ELISA
method using an Actichrome kit.
Statistical analysis
ANOVA, independent samples test, t-test, chisquare, variance analysis, and Pearson’s correlation
tests were used in statistical analyses using SPSS 13.0.
For data evaluation, descriptive statistical methods,
such as mean, standard deviation (SD), and minimum
and maximum values, were used. P value of <0.05 was
accepted as significant.
Results
Subjects included in the study were divided into 9
groups. The association of all groups with TAFI Ag
was investigated. Results of all parameters are given
for both patient and control groups in the Table.
Group 1: This group includes individuals with
metabolic syndrome who do not have a known
coronary artery disease and meet 3 or more of NCEP
ATP III criteria (n = 63) and healthy control subjects.
(n = 20). In this group, in the comparison of mean
TAFI Ag levels between metabolic syndrome group
and control group, they were found to be significantly
higher in the MS group (t = 3.92, P < 0.01), again in
this group, HOMA-IR levels were compared between
the MS group and the control group and they were
found significantly higher in patients with MS (t =
5.39 , P < 0.01). In patients with MS, triglyceride, total
cholesterol, and fasting blood glucose levels were
found to be higher while HDL levels were lower than
the control group (P < 0.05). No significant difference
was found between mean LDL values. Waist
circumference and BMI were found to be significantly
higher in the MS group (P < 0.01) (Figures 1 and 2)
Group 2: Patients with MS were examined in 2
subgroups; HOMA-IR > 2.5 (n = 19) and HOMA-IR
< 2.5 (n = 44) and these 2 groups were compared in
859
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Table 1. Results of all parameters for both patients and control groups.

SAP (mmHg; mean ± SD)
DAP (mmHg; mean ± SD)
BMI (kg/m2; mean ± SD)
Waist circumference (cm; mean ± SD)
FBG (mg/dL; mean ± SD)
Total cholesterol (mg/dL; mean ± SD)
LDL (mg/dL; mean ± SD)
HDL (mg/dL; mean ± SD)
Triglyceride (mg/dL; mean ± SD)
HOMA-IR (mean ± SD)
TAFI Ag (mean ± SD)

MS Group
n = 63

Control Group
n = 20

t

P

144 ± 24
91 ± 15
33 ± 5
110 ± 11
137 ± 59
215 ± 42
129 ± 37
44 ± 8
249 ± 208
4.3 ± 2.9
166 ± 74

117 ± 11
74 ± 6
24 ± 3
83 ± 12
84 ± 13
193 ± 24
121 ± 18
50 ± 13
117 ± 37
1.7 ± 1.2
114 ± 40

4.81
4.80
6.26
8.24
6.47
2.67
1.32
2.42
4.63
5.3
3.92

0.0005
0.0005
0.0005
0.0005
0.0005
0.0010
0.192
0.018
0.0005
0.0005
0.0005

BMI: Body Mass Index;
DAP: Diastolic Arterial Pressure;
MS: Metabolic Syndrome;
SAP: Systolic Arterial Pressure;
TAFI: Thrombin-Activatable Fibrinolysis Inhibitor;

FBG: Fasting Blood Glucose;
SD: Standard Deviation;
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Figure 1. Mean TAFI Ag levels in both MS and control groups.

Figure 2. HOMA-IR levels in both MS and control group.

terms of mean TAFI Ag levels. Although these levels
were found to be higher in the subjects with high
HOMA-IR values than those with normal values, the
difference was not statistically significant (Figure 3).

(n = 38). Although mean TAFI Ag values were found
to be higher in the subjects with total cholesterol value
of over 200 mg/dL than those with total cholesterol
values below 200 mg/dL, the difference was not
statistically significant. (Figure 4)

Group 3: MS patients were divided into 2 groups
according to their total cholesterol values; subjects
whose total cholesterol value < 200 mg/dL (n = 25)
and those whose total cholesterol value > 200 mg/dL
860

Groups 4 and 5: In group 4, although mean TAFI
Ag level was higher in the subjects with a triglyceride
value of over 150 mg/dL (n = 44) than those with a
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Figure 3. Fasting blood glucose (FPG), triglyceride, HDLcholesterol and LDL-cholesterol levels compared in
both MS and control groups.

Figure 4. Mean plasma TAFI Ag levels according to total
cholesterol values in MS patients.

value below 150 mg/dL (n = 19), the difference was
not statistically significant. There was a positive
correlation between triglyceride and TAFI Ag levels
in patients with metabolic syndrome (r = 0.25, P <
0.05); i.e., TAFI Ag level increased as the triglyceride
level increased. In group 4, where the patients with
MS were divided into 2 subgroups according to the
triglyceride levels, the lack of a significant difference
in TAFI Ag levels between those with a triglyceride
level below and above 150 mg/dL may be explained
by the smaller number of cases with a triglyceride
level < 150 mg/dL (n = 19). In group 5, although
TAFI Ag level was found to be higher in the subjects
with LDL level of >140 mg/dL than those under < 140
mg/dL, the relation between LDL level and ile TAFI
Ag level was not significant (Figures 5 and 6).

Groups 6 and 7: In group 6, patients with MS were
divided into 2 subgroups; those with
microalbuminurea (n = 18) and those with
normoalbuminurea (n = 45), and in group 7; those
who are normotensive (n = 14) and hypertensive (n =
49). Although TAFI Ag was found to be higher in
hypertensive and normoalbuminuric groups, the
difference was not statistically significant.
Group 8: In group 8, patients with MS were
divided into 2 subgroups by the HDL level. In
subgroup 1 (n = 49), HDL level was below 40 mg/dL
and 50 mg/dL in males and females, respectively. In
subgroup 2 (n = 14), it was above these levels. The
mean TAFI Ag level was detected to be higher in those
with a low HDL level; however, the difference was not
statistically significant (Figure 7).
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Figure 5. Relationship between triglyceride levels and plasma
TAFI Ag in MS patients.
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Figure 6. Mean plasma TAFI Ag levels according to triglyceride
values in MS patients.
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Group 9: In group 9, patients with MS were
grouped as those with a waist circumference above
and below 88 cm and 102 cm in males and females,
respectively. In addition, patients with MS were also
divided into 4 subgroups by their waist circumference,
irrespective of gender: 80-99 cm (n = 10), 100-109 cm
(n = 17), 110-119 cm (n = 24), and >120 cm (n = 12).
The highest mean TAFI Ag level was detected in those
with a waist circumference between 110 and 119 cm;
however, no statistically significant correlation was
detected between the mean TAFI Ag level and the
waist circumference in any of these subgroups (Figure
8).
Discussion
In metabolic syndrome in which many disorders
such as abdominal obesity, lipid metabolism
disorders, hypertension, diabetes, insulin resistance
with
or
without
glucose
intolerance,
microalbuminurea, thrombosis or tendency to
inflammation coexist, the mortality and morbidity of
coronary heart disease (CHD) increase. Insulin
resistance leads to susceptibility to metabolic
syndrome findings, such as dyslipidemia and
hypertension. In addition, it is a central metabolic
disorder that leads to the development of type II
diabetes. The loss of the balance between
prothrombotic and fibrinolytic factors is another
characteristics of metabolic syndrome. Studies

investigating the nature of the interaction between
hemostatic factors and the endothelial cells on the
surface of blood vessels demonstrated that metabolic
syndrome is a strong risk factor for arteriosclerotic
cardiovascular disease. In the large scale study of
Juhan V. in 2000, traditional risk factors were
compared both between each other and with TAFI Ag
values. In the present study, TAFI Ag values correlated
positively with BMI, systolic blood pressure, diastolic
blood pressure, and fibrinogen in males while they
correlated with age, systolic blood pressure, total
cholesterol, Apo B, fibrinogen, and IMT (intimamedia thickness) in females. After correction for age,
while no correlation was found in females between
TAFI Ag values and other parameters, significant
correlation was found between TAFI Ag values and
waist-hip ratio and blood pressure (15). In the present
study, TAFI Ag values were found to be significantly
higher in the metabolic syndrome group than in the
control group. However, no significant relation was
found in the metabolic syndrome group between
TAFI Ag values and BMI and hypertension. In many
studies (11,14,15), significant relation has been found
between TAFI and hypercholesterolemia. Yet, in the
present study, although TAFI values were higher in
the group with a cholesterol value of over 200 mg/dL
than those with a value below 200 mg/dl, the
difference was not statistically significant.
There are many studies demonstrating a positive
relation between TAFI activity and TAFI Ag (16,17).
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Figure 7. Mean TAFI Ag levels according to HDL-cholesterol
values in MS patients.
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Figure 8. Mean plasma TAFI Ag levels according to waist
circumference in MS patients.
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In the present study, TAFI Ag levels were examined. It
was established that, in metabolic syndrome, which is
one of the most important risk factors for coronary
heart disease, TAFI Ag levels were significantly higher
than the control group. In the present study, unlike
the study of Montserrat, higher TAFI Ag levels were
found in the hypertensive group with MS than the
normotensive MS group, but the difference was not
statistically significant.
In the study of Yoshimasa Aso. et al. (published in
the journal ‘Diabetes’ in 2005), it was advocated that
LDL-cholesterol should be taken into account in the
determination of plasma TAFI Ag in type 2 diabetes
patients and that both metabolic syndrome and
hypercholesterolemia accelerate inflammation in
combination, thus slowing fibrinolysis. It was also
established that direct inhibition of fibrinolysis was
related to high levels both in TAFI and PAI-1. Unlike
Yoshimasa Aso, in the present study, in patients with
metabolic syndrome, higher plasma values of TAFI
Ag were found in those with plasma LDL-cholesterol
level over 140 mg/dL than those with a corresponding
value under 140 mg/dL, but the difference was not
statistically significant. Again, in patients classified as
normoglicemic-impaired fasting glucose-diabetes,
according to the fasting blood glucose values, no
significant relation was found between fasting blood
glucose and plasma TAFI Ag levels. In the present
study, patients with metabolic syndrome were divided
into 2 subgroups (microalbuminuric and
normoalbuminuric) in that microalbuminurea has a
significant relation with endothelial vessel damage
and it was established that the increase in TAFI Ag
levels in metabolic syndrome was independent of
microalbuminurea.
When we compared triglyceride levels and TAFI
Ag levels in patients with metabolic syndrome, we
found a positive mild correlation between plasma
triglyceride levels and TAFI ag level (i.e., triglyceride
levels increased, so did TAFI Ag levels). It is not
known whether increase in TAF I Ag levels in
metabolic syndrome directly reflect the increase in
triglyceride levels or is the result of common effect of
other components of metabolic syndrome. However,
in the present study, it was established that the
important factor in the increase in plasma TAFI Ag

levels was the increase in triglyceride levels. Y.Hori et
al. investigated plasma TAFI levels and activity in
order to evaluate hypofibrinolysis, which is one of the
most common findings in obese type 2 DM patients.
They divided DM patients into 2 groups according to
their BMI ( BMI > 25 obese ve BMI <25 non-obese).
They found TAFI levels to be significantly higher in
DM patients than in controls. In obese patients with
DM, TAFI concentration and activity was found to be
significantly higher than non-obese DM patients and
controls. In conclusion, they found significant
correlation between plasma TAFI levels and HbA1c,
BMI, and insulin resistance (18). In the present study,
unlike the results of Y.Hori et al., although TAFI levels
were found to be significantly higher in patients with
metabolic syndrome, when insulin resistance was
calculated using the HOMA-IR formula. The
difference in TAFI Ag levels between those with high
HOMA-IR values and those with low values was not
statistically significant. Juhan V. investigated
cardiovasular risk factors, and found a positive
correlation between TAFI ag levels and
hypercholesterolemia (14). Similarly, A.Santamaria et
al., in their study on patients with coronary artery
disease, found a positive correlation between TAFI
levels and hypercholesterolemia (19). In the present
study, a positive correlation was found only between
triglyceride levels, which is one of the components of
metabolic syndrome, and TAFI Ag levels. No positive
correlation was found between other components of
metabolic syndrome and plasma TAFI Ag levels. We
believe that increased TAFI Ag levels may have
contributed to the prothrombotic state in metabolic
syndrome and that hypertriglyceridemia may play a
role in this contribution in view of the mild
correlation we found between TAFI and triglycerides.
In addition, other components of metabolic syndrome
may contribute to the increase in TAFI levels. This
contribution may be investigated with further studies
including higher number of participants.
Conclusions
These findings suggest that increased TAFI levels
in metabolic syndrome may contribute to
prothrombotic state and hypertriglyceridemia may
take part in this contribution.
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